Christopher Hite sold $8.2M of RPRX
EVP & Chairman, Partnering at Royalty Pharma plc. 150,000 shares at an average of $54.40, traded Jun 23, 2026, filed Jun 25, 2026.
Score components
- +20RoleChair
- +25Trade size$8.2M at market
- +5Share of holdings soldSold 21% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001814238-26-000009, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 23, 2026 | SOpen-market sale Class A Ordinary Sharesindirect: By SCH Investment Partners LLC10b5-1 | -32,408 | $54.11 | $1.8M | 676,991 | Jun 25, 2026 |
| Jun 23, 2026 | SOpen-market sale Class A Ordinary Sharesindirect: By SCH Investment Partners LLC10b5-1 | -117,592 | $54.47 | $6.4M | 559,399 | Jun 25, 2026 |
Related signals
Other insiders at Royalty Pharma plc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | Royalty Pharma plc | Marshall Urist EVP, Research & Investments | $236k 4,126 shares | -100% | |
| 36Weak | Royalty Pharma plc | Marshall Urist EVP, Research & Investments | $239k 4,126 shares | -50% | |
| 43Moderate | Royalty Pharma plc | Christopher Hite EVP & Chairman, Partnering | $5.9M 100,000 shares | -27% | |
| 38Weak | Royalty Pharma plc | Christopher Hite EVP & Chairman, Partnering | $6.0M 100,000 shares | -21% | |
| 50Moderate | Royalty Pharma plc | Terrance P. Coyne EVP & CFO | $646k 11,002 shares | -100% | |
| 38Weak | Royalty Pharma plc | Christopher Hite EVP & Chairman, Partnering | $7.3M 130,000 shares | -23% | |
| 41Moderate | Royalty Pharma plc | Marshall Urist EVP, Research & Investments | $508k 9,099 shares | -100% | |
| 31Weak | Royalty Pharma plc | Marshall Urist EVP, Research & Investments | $502k 9,098 shares | -50% | |
| 62Notable | Royalty Pharma plc | Terrance P. Coyne EVP & CFO | $3.5M 64,399 shares | -100% | |
| 41Moderate | Royalty Pharma plc | Marshall Urist EVP, Research & Investments | $722k 13,684 shares | -43% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.